INFIUnknown
INFINITY PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for INFINITY PHARMACEUTICALS, INC. (INFI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are INFI insiders buying or selling?
INFINITY PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 14 Form 4 filings for INFI: 7 buys ($13.1M) and 7 sells ($36.5M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Sep 12, 2023)
Total Form 4 filings
14
SEC EDGAR
Insider filers
4
Insider buys (7)
$13.1M
Insider sells (7)
$36.5M
Insider sentiment
Net sellingNet insider flow of $23.4M in net selling since March 2018.
Recent INFI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 12, 2023 | Adelene Q Perkins | Director | Sale | 410.2K | $0.07 | $28.7K | SEC ↗ |
| Aug 4, 2022 | Stephane Peluso | Chief Scientific Officer | Purchase | 15.0K | $0.66 | $9.9K | SEC ↗ |
| Feb 16, 2021 | Mark N Lampert | 10% Owner | Sale | 2.3M | $5.37 | $12.1M | SEC ↗ |
| Jan 26, 2021 | Mark N Lampert | 10% Owner | Sale | 5.8M | $4.14 | $24.2M | SEC ↗ |
| Dec 18, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 175.0K | $1.20 | $209.9K | SEC ↗ |
| Nov 30, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 100.0K | $1.30 | $130.0K | SEC ↗ |
| Nov 21, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 1.5M | $1.37 | $2.0M | SEC ↗ |
| Nov 16, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 905.9K | $1.35 | $1.2M | SEC ↗ |
| Oct 2, 2018 | Adelene Q Perkins | Chief Executive Officer | Sale | 5.0K | $2.82 | $14.1K | SEC ↗ |
| Aug 17, 2018 | Jeffery Kutok | Chief Scientific Officer | Sale | 14.3K | $2.00 | $28.7K | SEC ↗ |
| Jun 25, 2018 | Jeffery Kutok | Chief Scientific Officer | Sale | 14.3K | $2.00 | $28.7K | SEC ↗ |
| Jun 21, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 3.9M | $1.65 | $6.5M | SEC ↗ |
| Apr 11, 2018 | BVF PARTNERS L P/IL | 10% Owner | Purchase | 1.5M | $1.97 | $3.0M | SEC ↗ |
| Mar 7, 2018 | Adelene Q Perkins | Chief Executive Officer | Sale | 5.0K | $2.78 | $13.9K | SEC ↗ |
Showing the 14 most recent of 14 Form 4 filings for INFINITY PHARMACEUTICALS, INC..
Most active INFI insiders
- BVF PARTNERS L P/IL8 filings
- Adelene Q Perkins3 filings
- Jeffery Kutok2 filings
- Stephane Peluso1 filing
Ask anything about INFI insider activity
Use Trabud's AI agent to query INFINITY PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me INFI CEO purchases this year" or compare it against any other ticker.
Open the AI agentINFI insider trading FAQ
Are INFINITY PHARMACEUTICALS, INC. insiders buying or selling?
INFINITY PHARMACEUTICALS, INC. insiders reported no open-market purchases or sales in the last 12 months. Since March 2018, Trabud has recorded 14 Form 4 filings for INFI: 7 buys ($13.1M) and 7 sells ($36.5M). Over the full record that is net selling of $23.4M.
How many insiders trade INFI stock?
4 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for INFINITY PHARMACEUTICALS, INC.. The most recent filing was accepted on Sep 12, 2023.
Where does Trabud get INFI insider trading data?
All INFI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.